Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 2/20 | 0.43 |
| ▸ | MLNR | O43193 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392178 | 0.92 | CASR (0.52) | SMN1; SMN2CASRALDH1A1CHRM3LMNA | |
| SCHEMBL4400538 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2PPARAALDH1A1MEN1KMT2A | |
| SCHEMBL4396970 | 0.90 | KMT2A (0.48) | SMN1; SMN2PPARACASRMLNRCHRM3 | |
| SCHEMBL4393805 | 0.85 | CASR (0.62) | CASR | |
| Hydrochloric Acid SCHEMBL4400765 | 0.84 | CASR (0.61) | CASR | |
| SCHEMBL4391777 | 0.83 | CASR (0.53) | SMN1; SMN2CASRALDH1A1TP53TSHR | |
| SCHEMBL4401960 | 0.82 | ALDH1A1 (0.47) | SMN1; SMN2MLNRALDH1A1CHRM3RAB9A | |
| SCHEMBL4391840 | 0.82 | CHRM3 (0.48) | SMN1; SMN2CASRCHRM3 | |
| SCHEMBL14472841 | 0.82 | CASR (0.43) | SMN1; SMN2CASRALDH1A1LMNATSHR | |
| SCHEMBL4397067 | 0.82 | CASR (0.59) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | PROSKELIA SAS (FR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | HRH4, HRH2, RPS2 | SMN1; SMN2 1662/4885PPARA 3148/4885CASR 2192/4885 |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | RPS2, NOX5, PRMT5 | SMN1; SMN2 2522/4885PPARA 2438/4885CASR 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.